I think so, there are two large potential drivers. Confirmation from GSK around new production figures (and contract demand) and hopefully a license deal for ROW LANI with Phase 3 results.
BTA is still valued as a specie biotech but their products have massive markets. If they can crack these markets then the upside is quite large. $1-$2bn market cap could be achieved.
Looking back, I wish I bought more at 30c.
I think so, there are two large potential drivers. Confirmation...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)